![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 39, 28019-28025, September 24, 1999
From the hHR23B is one of two human homologs of the
Saccharomyces cerevisiae nucleotide excision repair (NER)
gene product RAD23 and a component of a protein complex that
specifically complements the NER defect of xeroderma pigmentosum group
C (XP-C) cell extracts in vitro. Although a small
proportion of hHR23B is tightly complexed with the XP-C responsible
gene product, XPC protein, a vast majority exists as an XPC-free form,
indicating that hHR23B has additional functions other than NER in
vivo. Here we demonstrate that the human NER factor hHR23B as
well as another human homolog of RAD23, hHR23A, interact specifically
with S5a, a subunit of the human 26 S proteasome using the yeast
two-hybrid system. Furthermore, hHR23 proteins were detected with S5a
at the position where 26 S proteasome sediments in glycerol gradient
centrifugation of HeLa S100 extracts. Intriguingly, hHR23B showed the
inhibitory effect on the degradation of 125I-lysozyme in
the rabbit reticulocyte lysate. hHR23 proteins thus appear to associate
with 26 S proteasome in vivo. From co-precipitation experiments using several series of deletion mutants, we defined the
domains in hHR23B and S5a that mediate this interaction. From these
results, we propose that part of hHR23 proteins are involved in the
proteolytic pathway in cells.
We have previously identified two distinct homologs of
Saccharomyces cerevisiae nucleotide excision repair
(NER)1 factor RAD23, in human
as well as in murine cells (1, 2). One of the human RAD23 homologs,
designated hHR23B, was found to be tightly complexed with the XPC
protein that plays an essential role in a subpathway of human NER
operating genome-wide (1). Although a vast majority of the XPC protein
is bound to hHR23B in vivo, another RAD23 homolog, hHR23A,
is also capable of interacting with XPC at least in vitro.
Using reconstituted cell-free NER reactions, we further showed that
both hHR23 proteins enhance the repair activity of XPC, suggesting a
possible functional interchangeability between the two RAD23 homologs
(3).
Amino acid sequence comparison of the yeast RAD23 and its mammalian
homologs revealed the existence of at least four distinct domains which
are well conserved among these proteins (Ref. 2, see also upper part of
Fig. 4A). First, this class of proteins is characterized by
a Ub-like sequence at the amino terminus. It was genetically shown that
this sequence is important for the biological function of yeast RAD23
(4). The second and fourth domains from the amino terminus are
ubiquitin-associated domains (5), suggesting a possible involvement of
the RAD23 as well as hHR23 proteins in certain pathways of ubiquitin
metabolism (2). By deletion and truncation analysis of recombinant
hHR23B protein, the third domain has been recently found to be
responsible for binding the XPC protein (6). These deletion studies
also revealed that the identified XPC-binding domain of hHR23B is
necessary and largely sufficient for the hHR23B NER function in
vitro: the Ub-like sequence and two copies of the
ubiquitin-associated domains appear to be dispensable for the core part
of NER. Therefore, it is conceivable that hHR23B, as well as other
members of this class of proteins, may be associated with ubiquitin
metabolic pathways outside the context of the core NER machinery. In
agreement with this idea, hHR23B exists in vivo in a large
excess over XPC (7, 8), suggesting it has extra functions without XPC.
To explore novel functions of the mammalian RAD23 homologs, it is of
great interest to search for proteins other than XPC which interact
with the hHR23 proteins. For this purpose, a yeast two-hybrid
expression library was screened using hHR23B as a bait. Here we report
the interaction of the hHR23 proteins with a 26 S proteasome subunit,
S5a, indicating the association of the RAD23 homologs with the
ubiquitin-dependent protein degradation machinery.
Yeast Two-hybrid Screening--
The yeast two-hybrid screening
was performed with the Matchmaker Two-Hybrid System
(CLONTECH). The entire cDNA for hHR23B was
fused in-frame with the GAL4 DNA-binding domain in pGBT9 vector (9).
The resulting plasmid, pGBT-hHR23B, was used for transformation of a
yeast strain, HF7c, and a Trp+ clone was selected. A human
cDNA library for the two-hybrid screening was constructed with
TimeSaver cDNA synthesis kit and Directional cloning toolbox (both
from Amersham Pharmacia Biotech). Complementary DNAs were synthesized
with NotI/oligo(dT) primers and poly(A)+ RNA
from an SV40-transformed fibroblast cell line, WI38VA13. After the
second strand synthesis, the cDNAs were ligated to EcoRI adaptors and then digested with NotI, resulting in
double-stranded cDNA fragments bearing EcoRI and
NotI overhangs on the upstream and downstream ends,
respectively. The cDNAs were subsequently cloned into pGAD424
vector encoding the GAL4 activation domain (9), and introduced into
Escherichia coli, DH5 Glycerol Gradient Sedimentation Analysis--
Cytoplasmic S100
fraction was prepared from HeLa cells as described previously (11). The
HeLa S100 (7 mg of protein) was supplemented with ATP to a final
concentration of 2 mM, and incubated on ice for 1 h.
The extract was overlaid onto a 10-40% glycerol gradient (30 ml) in
25 mM Tris-HCl (pH 7.5), 1 mM dithiothreitol, 2 mM ATP, and subsequently centrifuged at 22,500 rpm
(83,000 × g) for 22 h at 4 °C. One-milliliter
fractions were collected from the bottom of the tube. The proteasome
activity of each fraction (150 µl) was assayed as described
previously (12).
Immunoprecipitation--
Each of anti-p45 monoclonal antibody
and anti-ubiquitin monoclonal antibody (2C5; MBL Co. Ltd., Japan), were
mixed with Protein G-Sepharose (Amersham Pharmacia Biotech),
respectively, in buffer C (20 mM Tris-HCl (pH 7.9), 200 µM EDTA, 20% glycerol, 0.1 M KCl, 2 mM ATP, 5 mM MgCl2, 0.1% Nonidet
P-40, 0.25 mM PMSF, 10 µM 2-mercaptoethanol) containing 200 µg/ml bovine serum albumin at 4 °C for 30 min with rotation. The beads were then washed three times with buffer C. The
antibody bound-Sepharose beads (5 µl) were incubated with 150 µg of
whole cell extract prepared from HeLa cells (13) in 80 µl of buffer C
at 4 °C for 1 h with rotation. The mixture was centrifuged, and
the precipitates were washed three times with buffer C. The bound
proteins were extracted by boiling in SDS sample buffer, separated by
8% SDS-PAGE, and analyzed by immunoblotting with anti-hHR23B and
anti-XPC antibody.
Preparation of Recombinant hHR23, S5a, and NEDD8
Proteins--
Recombinant hHR23A and hHR23B proteins (designated as
rhHR23A and rhHR23B) as well as a series of deletion mutants of hHR23B were expressed in E. coli and purified as described
previously (6). Ub-rhHR23B, which has the ubiquitin sequence instead of the original Ub-like sequence on its NH2 terminus, was
constructed. Ubiquitin cDNA was obtained from a human cDNA
library using polymerase chain reaction technique, and inserted
in-frame into pET-24d (Novagen) which harbors hHR23B with an
NH2-terminal deletion encoding amino acids 73-409 (6). The
resulting plasmid expresses hHR23B with the ubiquitin sequence on its
NH2 terminus instead of the Ub-like domain in E. coli. The expression and purification of the protein was performed
as described previously (6). Recombinant human S5a (designated as rS5a)
protein was expressed in E. coli BL21(DE3) using pET3a
vector (Novagen). Cells containing the S5a construct were grown at
30 °C, induced with 1 mM
isopropyl- Protein Degradation Assay--
Lysozyme was iodinated with
Na125I using Iodo-Beads (Pierce) according to the
manufacture's instruction. Assay of 125I-lysozyme
degradation was performed by the procedure described previously (15)
with the following modifications. Briefly, 40 µl of the rabbit
reticulocyte extracts were incubated for 30 min at 37 °C in a total
volume of 100 µl which contained 50 mM Tris-HCl (pH 7.5),
5 mM MgCl2, 1 mM dithiothreitol,
and either an ATP-regenerating system (2 mM ATP, 10 µg/ml
creatin phosphokinase, 10 mM phosphocreatin) or
ATP-depleting system (1 µg/ml hexokinase, 10 mM glucose)
prior to adding 125I-lysozyme (20,000 cpm). After
incubation for 1 h at 37 °C, the reaction was terminated by
addition of 575 µl of 10% trichloroacetic acid with 125 µl of 4%
of bovine serum albumin as a carrier. Radioactivity in the supernatants
and the precipitated pellets were counted by In Vitro Binding Assay--
The rhHR23B-6His (full-length,
truncated, or Ub-fused) proteins (30 pmol) or the rNEDD8-6His protein
(30 pmol) were incubated with non-tagged rS5a protein (3 pmol) in
buffer H (20 mM HEPES (pH 7.9), 0.1 M NaCl,
20% glycerol, 0.1% Nonidet P-40, 200 µg/ml bovine serum albumin,
0.25 mM PMSF, 10 µM 2-mercaptoethanol) on ice
for 1 h. Each protein sample was mixed with a 2-fold volume of a
suspension of nickel-chelating Sepharose beads in buffer H containing
20 mM imidazole, and incubated for 1 h at 4 °C. The mixture was centrifuged, and the beads were washed three times with
buffer H containing 60 mM imidazole. The bound proteins
were extracted by boiling in SDS sample buffer, separated by 10%
SDS-PAGE, and analyzed by immunoblotting with anti-S5a antibody. The
in vitro binding assay for a series of 6His-tagged rS5a
mutants (30 pmol) with either non-tagged rhHR23A or rhHR23B (3 pmol)
was performed as described above except that either anti-hHR23A or
anti-hHR23B antibody was used for immunoblotting.
Competition Assay--
The rhHR23B-6His protein (3 pmol) was
mixed with various amounts of competitor in 100 µl of buffer H, and
then incubated with GST-rS5a (15 pmol) on ice for 1 h. Both the
rhHR23B-(1-87) protein (containing the NH2-terminal
Ub-like portion of hHR23B) and the ubiquitin molecule were used as
competitor. Then glutathione-Sepharose beads were added and mixed at
4 °C overnight. The mixture was centrifuged, and the resin was
washed with buffer H. The bound proteins were extracted by boiling in
SDS sample buffer, separated by 10% SDS-PAGE, and analyzed by
immunoblotting with anti-hHR23B antibody.
Antibodies--
Antibodies against hHR23B, hHR23A, and XPC were
obtained as described previously (7). Anti-S5a antibody was obtained by immunization of rabbits with a 6His-tagged rS5a, and purified with
affinity chromatography at MBL Co. Ltd. The serum of anti-p45 monoclonal antibody was kindly provided by Klavs B. Hendil.
Other Methods--
SDS-PAGE was performed as described by
Laemmli (16). For the immunoblotting, proteins separated on SDS gels
were electrotransferred onto polyvinylidene difluoride membrane
(Immobilon-P; Millipore), at 8 V/cm overnight in ice-cold transfer
buffer (50 mM Tris, 38.4 mM glycine, 0.01%
SDS, 15% methanol). The membranes were successively incubated in
blocking buffer (5% skim milk in 25 mM Tris-HCl (pH 7.5),
0.15 M NaCl, 0.1% Tween 20), with first antibody in
blocking buffer, and then with anti-rabbit or anti-mouse
F(ab')2 antibody conjugated with horseradish peroxidase
(Amersham Pharmacia Biotech) in blocking buffer. Detection was carried
out with SuperSignal Substrate (Pierce) according to the manufactures
instructions. Protein concentration was measured according to the
method of Bradford (17), using Bio-Rad Protein Assay reagent (Bio-Rad Laboratories) and bovine serum albumin as a standard.
hHR23B Interacts with S5a, a Component of the Human 26 S Proteasome
Regulatory Subunit--
To isolate proteins which interact with
hHR23B, we performed a yeast two-hybrid screening. The interaction of
the hHR23B fusion protein with its known partner, XPC, was confirmed
both by histidine prototrophy conferred on the yeast strain and by
an intense blue color upon in situ hHR23B Interacts with 26 S Proteasome in Cell Extracts--
The
above results of a yeast two-hybrid screening showed that hHR23
proteins interact with S5a, suggesting that hHR23 proteins might be
able to associate with 26 S proteasome via the interaction with S5a
in vivo. Such an association can be analyzed by immunoblot analysis of fractions of cell extracts separated through glycerol gradient centrifugation after preincubation of the extracts in the
presence of 2 mM ATP, which promotes assembly of 26 S
proteasome in cell extracts (20). Thus, identification of putative
subunits of the proteasome can be determined by analysis of their
distribution over the gradient. When the distribution of hHR23B was
analyzed, the protein was found to migrate with S5a peaking at fraction 9 (Fig. 1A), although the vast
majority of hHR23B was found in slower sedimenting fractions (Fig.
1A). Under these conditions, most of the 26 S proteasome
activity was observed in fraction 9 (Fig. 1B). Similar
results were obtained in the case of hHR23A experiments (data not
shown). We previously reported that the sedimentation coefficient of
the XPC-hHR23B complex is 6.2 S (1). Furthermore, in the absence of
ATP, hHR23 proteins were sedimented with 19 S regulatory complex
through glycerol gradient centrifugation (data not shown). To explore
the association between hHR23 proteins and 26 S proteasome in a
different way, HeLa whole cell extracts were used for
immunoprecipitation with monoclonal antibody raised against p45, one of
the regulatory components of 26 S proteasome (21). Fig.
2 indicates that a part of hHR23B
associates with the proteasome regulatory complex containing S5a in the
cell extracts, although co-precipitation of XPC was undetected. These
results strengthened our hypothesis that hHR23 proteins are associated with 26 S proteasome at least through the interaction with S5a in
cell extracts.
Inhibition of Lysozyme Degradation by hHR23B--
To explore the
physiological meaning of the interaction between hHR23 proteins and 26 S proteasome, the effects of hHR23B on 125I-lysozyme
degradation was demonstrated using rabbit reticulocyte extracts. It was
previously reported that the Arabidopsis S5a inhibits the
degradation of multiubiquitinated lysozyme in reticulocyte extract
(22). As shown in Fig. 3A,
human S5a was sufficient to interrupt 125I-lysozyme
degradation in reticulocyte extracts as well (lane 2).
Intriguingly, 125I-lysozyme degradation was also inhibited
by the addition of rhHR23B-6His in a dose-dependent manner
(lanes 3-6). It is possible that rhHR23B-6His works as a
competitor for 125I-lysozyme degradation by proteasome in
reticulocyte extracts, because hHR23 proteins are associated with the
S5a subunit of 26 S proteasome as described above. Surprisingly, no
proteolysis of rhHR23B-6His was observed during a 3-h incubation (Fig.
3B). These data indicate that the physiological relation
lies between hHR23B and 26 S proteasome. It has been generally accepted
that protein substrate for the ubiquitin-dependent
proteolysis would be multiubiquitinated by ubiquitination and degraded
by 26 S proteasome in rabbit reticulocyte extracts. It is likely,
therefore, that the Ub-like domain of the hHR23 proteins is very
competitive with multiubiquitin chain.
Determination of the S5a-binding Domain in hHR23B--
To further
explore the meaning of the interaction between hHR23 proteins and S5a,
several experiments were performed using recombinant S5a (rS5a)
expressed in E. coli. We previously identified the region in
hHR23B that affects the interaction with XPC using 6His-tagged
recombinant hHR23B (rhHR23B-6His) proteins with various deletion mutant
(6). These mutant proteins were used to identify the region responsible
for the interaction with S5a. Mutant rhHR23B-6His proteins, summarized
in Fig. 4A, were adsorbed to
nickel-chelating Sepharose beads, and then incubated with non-tagged
rS5a protein. Co-precipitation of S5a was assessed by immunoblotting.
As shown in Fig. 4B, rhHR23B lacking 72 amino acids from the
NH2 terminus failed to interact with S5a (lane
3), whereas the polypeptide corresponding to only 87 amino acids
from the NH2 terminus of hHR23B, designated as
rhHR23B-(1-87), was sufficient to precipitate the S5a molecule
(lane 12). As we reported previously, the
NH2-terminal region (amino acids 1 to 79) in hHR23B shares
a homology to ubiquitin (1). Identification of the Ub-like sequence as
the S5a-interacting domain of hHR23B raised the possibility that the
S5a protein binds to any proteins which are conjugated with ubiquitin.
To examine whether this is the case, we performed competition
experiments using either free ubiquitin itself or the
NH2-terminal Ub-like domain of hHR23B. As shown in Fig.
5, hHR23B was detected in the precipitate
fraction with GST-rS5a and glutathione-Sepharose beads (lane
3). Interestingly, the amount of precipitated hHR23B by GST-rS5a
was dramatically decreased by the addition of rhHR23B-(1-87) in a
concentration-dependent manner (Fig. 5, lanes
4-6), while the same concentration of ubiquitin monomer only
slightly affected the interaction between GST-rS5a and rhHR23B (Fig. 5,
lanes 7-9). One might argue that the S5a protein
efficiently binds both Ub-like domains and ubiquitin itself only when
fused to other proteins, via the COOH terminus, because the
hHR23B-(1-87) has extra 8 amino acids beyond the Ub-like domain. To
test this hypothesis, we prepared a chimeric protein, in which the
Ub-like in hHR23B was replaced by ubiquitin itself (Ub-rhHR23B-6His).
S5a was incubated with either rhHR23B-6His or Ub-rhHR23B-6His and
pulled down with nickel-chelating Sepharose beads. As shown in Fig.
6A, S5a was hardly
co-precipitated with Ub-rhHR23B-6His (lane 3), while
rhHR23B-6His efficiently binds S5a (lane 4). To further
confirm the specificity of the interaction between hHR23B and S5a,
another binding experiment was performed using one of the Ub-like
proteins, NEDD8 (14). NEDD8 shows high homology to ubiquitin (81 amino
acids which show 58% identity and 79% similarity with ubiquitin), but
its role in proteolysis has not been identified. Fig. 6B
shows the specific interaction between hHR23B and S5a (lane
4) but not between NEDD8 and S5a (lane 3). These
results indicate that the Ub-like domain of hHR23B is necessary and
sufficient to interact with S5a, and establish the specificity of S5a
for binding to the Ub-like sequence.
Determination of the hHR23-binding Domain in S5a--
To localize
the region in S5a that mediates the interaction with both hHR23
proteins, a series of truncated S5a proteins was also prepared (Fig.
7A). Amino acid sequence
comparison among the S5a homologs in eukaryotes revealed a highly
conserved region in the COOH-terminal half, which contains some
hydrophobic amino acids (23). To examine binding to both hHR23
proteins, the 6His-tagged rS5a (full-length or truncated) proteins were
incubated with either non-tagged rhHR23B or rhHR23A. The tagged
proteins were pulled down with nickel-chelating Sepharose beads, and
the presence of both rhHR23 proteins in the precipitate fractions was
assessed by immunoblotting. As shown in Fig. 7, the rhHR23 proteins
itself did not bind nickel-chelating Sepharose beads (Fig. 7,
panels B and C, lane 2). In the
presence of the full-length 6His-tagged rS5a, detectable amounts of
both rhHR23 proteins were precipitated (Fig. 7, panels B and
C, lane 3), indicating that not only hHR23B but
also hHR23A formed a physical complex with rS5a in vitro as expected from the two-hybrid assay. When no more than 262 amino acids
were deleted from the NH2 terminus, both hHR23 proteins were still bound to the mutant rS5a proteins (Fig. 7, panels
B and C, lanes 4-6). As for the deletion
from the COOH terminus, both hHR23 proteins were detected in the bound
fractions with the 6His-tagged rS5a lacking amino acids from residue
Gly344 onwards to the COOH terminus (Fig. 7, panels
B and C, lane 7). However, further deletion
toward the NH2 terminus abolished the hHR23 binding
activities almost completely (Fig. 7, panels B and C, lanes 8 and 9). These results
indicate that the hHR23-binding domain is located within the region
covering amino acids Met263 to Pro343 of S5a
(Fig. 8A). To further define
the region for hHR23-binding in S5a, another series of mutant S5a
proteins were subjected to the binding assay (Fig. 8A). Fig.
8 (panels B and C) shows that polypeptide
corresponding to amino acid 263-307 of S5a efficiently binds both
hHR23B and hHR23A (lane 6). Moreover, amino acids from Met263 to Met281 are necessary for the binding
(Fig. 8, B and C, lanes 3 and
4).
RAD23 was originally isolated in a screening for
ultraviolet-sensitive mutants (24) and was the first Ub-like protein
identified in yeast (4). The Ub-like sequence of RAD23 was shown to be important for its NER function in yeast. However, a requirement for the
Ub-like sequence in hHR23B is not clear at least in the cell-free NER
system (6). Previously, we have examined the interaction of hHR23B and
XPC proteins by using several deletion mutants of hHR23B protein. The
XPC-binding domain was mapped near the COOH terminus of hHR23B, to a
region with a putative amphipathic helical character but the
NH2-terminal Ub-like sequence was not absolutely required
for the interaction. Therefore, it is unlikely that the Ub-like
sequence plays a crucial role in complex formation between XPC and
hHR23B. Furthermore, the majority of hHR23 proteins are free from XPC
in human cells (7, 8). These results strongly suggest that the hHR23
proteins have an additional role in cells other than the complex
formation with XPC.
Physiological Interaction between hHR23B and 26 S
Proteasome--
Here we described the physical association between
hHR23 proteins and S5a, one of the regulatory subunits of 26 S
proteasome, using a yeast two-hybrid system. Furthermore, we report
here that hHR23B associates with 26 S proteasome by both the glycerol
gradient sedimentation and co-immunoprecipitation (Figs. 1 and 2). As
shown in the yeast two-hybrid experiment, the interaction of
NH2-terminal-truncated S5a with hHR23B was stronger than
that of intact S5a (Table, lines 6-9). This finding can be explained
in two ways. One is that the NH2-terminal portion of S5a
reduces the interaction of S5a with hHR23B. The other is that the
deletion mutants have a better conformation to interact with hHR23B
than the full-length S5a when expressed as a fusion protein with GAL4
DNA-binding domain. Recently, it was reported that RAD23 interacts with
yeast 26 S proteasome at least through Cim5, an ATPase subunit, via its
NH2-terminal portion (25), whereas Mcb1, an yeast
counterpart of human S5a, has not been proven to interact with RAD23.
It was also reported that hemagglutinin-tagged RAD23 is rapidly
degraded in a 26 S proteasome-dependent manner in yeast
(25). These data raise the possibility that the hHR23 proteins migrate
with 26 S proteasome to be degraded as same as in yeast. However, our
results propose the different possibility. We demonstrated here that
hHR23B inhibited the lysozyme degradation in reticulocyte extracts
without its own degradation (Fig. 3). This stability of hHR23B supports
the previous finding that the native RAD23 protein is extremely stable,
and Ub-like domain in RAD23 does not mediate its degradation in yeast
(4). Thus we propose the model that hHR23B somehow regulates the
proteolysis of the ubiquitinated protein by 26 S proteasome via the
specific interaction with S5a, rather than 26 S proteasome simply
degrades hHR23 proteins as its target.
The Ub-like Domain of hHR23 Proteins and the Multiubiquitin
Chain-binding Domain of S5a Are Responsible for Interaction between
hHR23 Proteins and S5a--
We demonstrated that the Ub-like domain of
hHR23B is necessary to interact directly with S5a (Fig. 4B,
lanes 4 and 13). This result corresponds well
with the previous finding that the Ub-like domain of hHR23B is
sufficient to interact with 26 S proteasome in HeLa cell extracts (25).
Our present paper is the first report to indicate clearly that one of
the hHR23-interacting protein in the 26 S proteasome is S5a in
mammalian cells. While rhHR23B-(1-87) protein has extra sequences (8 amino acids) beyond the Ub-like domain, we obtained evidence that the
first 72 amino acids (which show 32% identity and 58% similarity with
ubiquitin) are responsible for the binding with the multiubiquitin
chain binding protein S5a (see Fig. 4B, lane 4).
It is obvious from the previous report by van Nocker et al.
(26) as well as our present data that S5a has only a poor affinity to
the ubiquitin monomer. On the other hand, we previously reported that
the majority of hHR23 proteins exist as a monomer form in cell extracts
(3). Our present results indicate that the Ub-like domain of the hHR23
proteins has a high affinity for S5a as a monomer (Figs. 5 and
6A). In contrast to this, neither Ub-rhHR23B nor NEDD8,
which shows high homology to ubiquitin, can interact with S5a (Fig. 6).
These results strongly suggest that S5a has a high preference for
binding to the Ub-like domain of hHR23 proteins. Watkins et
al. (4), however, previously reported that Ub-RAD23 can
functionally replace the UV damage response of the native RAD23 protein
in yeast. Therefore, it is also likely that Ub-hHR23B is able to
substitute the physiological function of native hHR23B in human cell.
In addition we mapped the hHR23-binding region in S5a. So far, the S5a
homolog has been isolated from S. cerevisiae,
Arabidopsis, Drosophila, mouse, and human (23,
26-30), and several lines of evidence have been obtained that S5a is a
multiubiquitin chain-binding protein. Based on amino acid sequence
alignments, it was noted that S5a homologs harbor a highly conserved
sequence starting from the specific tetrapeptide, GVDP (23). Two
repeats of this sequence were identified in higher eukaryotic proteins,
while the S. cerevisiae S5a homolog has only one. The
hHR23-binding region comprised of 81 amino acids was mapped between the
GVDP tetrapeptide repeats in S5a (Fig. 7). Recently, three independent
groups reported the identification of the multiubiquitin chain-binding
site in S5a homologs (31-33). Especially, two multiubiquitin-binding
sites were identified in human S5a, designated as PUbS1
(Met196-Ala241) and PUbS2
(Met263-Asp307) (33). PUbS1 has a GVDP
tetrapeptide and a conserved hydrophobic amino acid stretch. PUbS2
lacks the GVDP tetrapeptide but has a hydrophobic amino acid stretch
which is also conserved among higher eukaryotes. PUbS2 was shown to
exhibit higher affinity for multiubiquitin chain compare with PUbS1
(33). Surprisingly, the region responsible for the interaction with
hHR23 proteins in S5a is identical to the sequence of PUbS2 (Fig.
8A). These results indicate that a monomer of the Ub-like
domain of hHR23B is able to bind to the multiubiquitin chain-binding
region of S5a and support our hypothesis that hHR23 proteins might be
competitive with multiubiquitin chain. Our experiments using a series
of deletion mutants of hHR23-binding domain of S5a indicate further
that the stretch of amino acids NH2-terminal to the
hydrophobic region (IAYAM) are necessary for binding activity (Fig. 8,
B and C, lanes 4 and 5). It
was reported that the presence of amino acids NH2-terminal to the hydrophobic region increased the amount of multiubiquitin chain
bound for PUbS2 (33). These results thus indicate that the site for
hHR23-binding overlaps with the site for multiubiquitin-binding in S5a.
However, it remains to be determined whether the amino acids
NH2-terminal to the hydrophobic region of S5a are
sufficient to interact with the hHR23 proteins, and whether hHR23
proteins and the ubiquitin polymer could compete with each other for
binding to S5a. These issues are now under investigation in our laboratory.
It is well known that DNA damage causes a significant problem for
eukaryotic cells (34). To facilitate repair processes prior to DNA
replication and cell division, the cell cycle is rigidly controlled in
response to DNA damage. Proteolytic process is one pathway to restrict
the cell cycle (35). It is obvious that the Ub-like domain of RAD23 is
responsible both for UV damage response (4) and to interact with 26 S
proteasome in yeast (33). From the strong conservation in structure and
function of yeast and human repair factors, it is likely that the
Ub-like sequence of hHR23 proteins is also responsible for UV damage
response in mammalian cells via the proteolytic pathway.
We thank Yoshiaki Ohkuma and Peter J. van der
Spek for stimulating and critical comments on all data, Sharad Kumar
for providing cDNA for NEDD8, and our colleagues for helpful discussions.
*
This work was supported in part by grants from the Ministry
of Education, Science, Sports, and Culture of Japan, the Takeda Science
Foundation, and the Biodesign Research Program of RIKEN (The Institute
of Physical and Chemical Research).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
Supported by Fellowships in Cancer Research of the Japan
Society for the Promotion of Science for Young Scientists. Current address: Cellular Physiology Laboratory, RIKEN (The Institute of
Physical and Chemical Research), 2-1 Hirosawa, Wako, Saitama 351-0198, Japan.
§§
To whom correspondence should be addressed: Institute for
Molecular and Cellular Biology, Osaka University, 1-3 Yamada-oka, Suita, Osaka 565-0871, Japan. Tel.: 81-6-6879-7975; Fax:
81-6-6877-9382; E-mail: fhanaoka@imcb.osaka-u.ac.jp.
The abbreviations used are:
NER, nucleotide
excision repair;
hHR23, human homolog of RAD23;
Ub, ubiquitin;
PMSF, phenylmethylsulfonyl fluoride;
PAGE, polyacrylamide gel
electrophoresis;
6His, hexahistidine;
GST, glutathione
S-transferase.
Interaction of hHR23 with S5a
THE UBIQUITIN-LIKE DOMAIN OF hHR23 MEDIATES INTERACTION WITH S5a
SUBUNIT OF 26 S PROTEASOME*
§,
¶,
,
,
,
, and
§§
Institute for Molecular and Cellular
Biology,
Cellular Physiology
Laboratory, RIKEN (The Institute of Physical and Chemical Research),
2-1 Hirosawa, Wako, Saitama 351-0198, Japan, the ** Tokyo
Metropolitan Institute of Medical Science, 3-18-22 Honkomagome,
Bunkyo-ku, Tokyo 113-8613, Japan, and the

Department of Cell Biology and Genetics,
Medical Genetic Center, Erasmus University, P. O. Box 1738, 3000DR Rotterdam, The Netherlands
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
. The plasmid DNA was isolated from
7.8 × 107 E. coli colonies. The yeast
strain bearing pGBT-hHR23B was further transformed with the cDNA
library, and positive clones were selected by histidine prototrophs.
The His+ clones were further verified for
-galactosidase
activity using a filter lift assay (10).
-D-thiogalactopyranoside for 3 h,
collected by centrifugation of approximately 1 liter of culture, washed
with 50 mM Tris-HCl (pH 7.5) containing 10% glycerol, and
suspended in 20 mM sodium phosphate (pH 6.8), 0.3 M NaCl, 0.25 mM PMSF. The suspension was
incubated on ice for 15 min with 1 mg of lysozyme/ml, frozen in liquid
nitrogen, and thawed at 4 °C. The lysate was adjusted to 35%
saturation of ammonium sulfate (0.164 g of solid/ml). The precipitates
were collected by centrifugation (20,000 × g, 30 min),
dissolved in 20 mM sodium phosphate (pH 6.8) containing
0.25 mM PMSF and then dialyzed against 20 mM
sodium phosphate (pH 6.8) containing 0.8 M ammonium
sulfate. After removal of insoluble materials by centrifugation, the
dialysate was loaded on a 1-ml butyl-Sepharose 4FF column (Amersham
Pharmacia Biotech) equilibrated with 20 mM sodium phosphate
(pH 6.8) containing 0.8 M ammonium sulfate. The column was
washed with the same buffer and bound proteins were eluted with 40 ml
of a decreasing ammonium sulfate gradient from 0.8 to 0 M.
rS5a, detected by SDS-PAGE and Coomassie Brilliant Blue staining, was
eluted during the last part of the gradient. The fractions containing
rS5a were pooled. After the dialysis against 20 mM sodium
phosphate (pH 6.8) containing 0.25 mM PMSF, the dialysate
was loaded on a 1-ml Hi-Trap Q-Sepharose column (Amersham Pharmacia
Biotech) equilibrated with the same buffer. After the column was washed
with an excess amount of the same buffer, bound proteins were eluted
with 20 mM sodium phosphate (pH 6.8), 0.25 mM
PMSF, 1 M NaCl. The peak fractions of rS5a were stored at
80 °C. S5a was also expressed as 6His- or GST-tagged versions
using 6HisT-pET11d or pGEX-2T(+) vector, respectively. The tagged rS5a
proteins were purified by nickel-chelating Sepharose (for 6His-tagged
proteins) or glutathione-Sepharose (Amersham Pharmacia Biotech) column
chromatography (for GST-tagged proteins). For generation of various
types of S5a deletion mutants, 5' primers were designed with
NdeI restriction sites at selected internal methionine
codons. 3' Primers containing EcoRI restriction sites were
also designed to generate COOH-terminal deletion mutants. The
polymerase chain reaction products were inserted into 6HisT-pET11d vector for expression. A series of deletion mutants of S5a was expressed and purified as described above. NEDD8 (14) was expressed as
6His-tagged version using pET24a vector. The tagged NEDD8
(rNEDD8-6His) protein was purified as described above.
spectrophotometry
(WALLAC, WIZARD 1840). To assess the effect of S5a or hHR23B on the
125I-lysozyme degradation, each recombinant proteins were
incubated with reticulocyte extracts for 30 min on ice before the
addition of 125I-lysozyme. In experiments designed to
demonstrate the stability of rhHR23B-6His, rhHR23B-6His was incubated
at 37 °C for 1 h in reticulocyte extracts and collected by
nickel-chelating Sepharose beads as described above. Then, the
collected proteins were subjected to 12% SDS-PAGE, and detected by
monoclonal antibody raised against pentahistidine (QIAGEN).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-galactosidase assay
(Table I, line 4). These results indicate
that hHR23B was expressed and interacted specifically with a known
natural target molecule in yeast as reported previously (18). The
screening of 1.5 × 107 yeast transformants yielded 20 candidate His+ and LacZ+ clones, 17 of which
contain cDNA encoding the human S5a protein, one of the regulatory
subunits of 26 S proteasome (19). One clone covers full-length of the
S5a cDNA, the others encode S5a with NH2-terminal
truncation of various size, suggesting that the COOH-terminal part of
S5a may be responsible for interaction with hHR23B. To confirm the
specificity of the observed interaction, pGAD plasmids were isolated
from several clones, and reintroduced into yeast in combination of
pGBT-hHR23B. As expected, the histidine prototrophy and
-galactosidase activity were observed in yeast expressing both S5a
protein and hHR23B (Table I, lines 6-9). It should be noted that the
interaction of truncated S5a with hHR23B was stronger (lines 7-9) than
that of intact S5a (line 6) as determined in the
-galactosidase
assay (see "Discussion"). Furthermore, another human homolog of
RAD23, hHR23A, was also found to interact with S5a (Table I, line 11).
S5a is known as a multiubiquitin chain-binding protein. Since both
hHR23 proteins have highly conserved Ub-related sequences on
NH2 termini (1, 2), we speculated that these sequences are
involved in the interaction with S5a.
Protein-protein interactions assessed by the yeast two-hybrid system

View larger version (43K):
[in a new window]
Fig. 1.
Co-fractionation of hHR23 proteins with the
26 S proteasome through glycerol density sedimentation. HeLa S100
was sedimented on a 10-40% glycerol density gradient by
centrifugation in the presence of 2 mM ATP, and fractions
were collected. A, the distribution of hHR23B and S5a was
assessed by immunoblotting. Proteins (present in 150 µl of each
fraction) were precipitated with cold acetone and subjected to
immunoblot analysis. fr., fraction; I, 10%
input. B, Measurement of the proteasome activity. S values
are indicated with arrowhead. The open squares
represent the proteasome activity in the absence of 0.02% SDS.
Closed circles represent the proteasome activity in the
presence of 0.02% SDS. Numbers at the bottom of
panel B correspond to the fraction numbers of panel
A.

View larger version (20K):
[in a new window]
Fig. 2.
Co-immunoprecipitation of 26 S proteasome and
hHR23B from HeLa whole cell extract. Antibody bound-Sepharose
beads were incubated with HeLa whole cell extract in buffer C at
4 °C for 1 h with rotation. Bound proteins were separated by
8% SDS-PAGE. 10% input of HeLa whole cell extract is shown in
lane 1. Anti-ubiquitin antibody (anti-Ub) served
as a negative control (lane 2). To precipitate the
proteasome complex, anti-p45 antibody (anti-p45) was used
(lane 3). XPC, a known partner of hHR23B, and hHR23B were
assessed by immunoblotting using anti-XPC or anti-hHR23B antibodies,
respectively.

View larger version (30K):
[in a new window]
Fig. 3.
Inhibition of 125I-lysozyme
degradation by rhHR23B-6His. A,
125I-lysozyme was incubated with rabbit reticulocyte
extracts at 37 °C for 1 h. Proteolysis of
125I-lysozyme was measured in the presence of either rhS5a
or rhHR23B-6His. Lane 1 shows the ATP-dependent
125I-lysozyme degradation. Relative degradation of
125I-lysozyme in the presence of rhS5a (20 µg) was shown
in lane 2, and in the presence of rhHR23B-6His (1, 5, 20, and 30 µg) was shown in lanes 3-6, respectively. Each
value was the mean ± S.D. of at least three independent
experiments. B, the stability of rhHR23B-6His (20 µg) in
the rabbit reticulocyte lysate was assessed. After incubation at
37 °C for the indicated time above each lane, the materials bound to
the nickel-chelating Sepharose beads were recovered. The presence of
precipitated hexahistidine-tagged protein was detected by
immunoblotting using anti-pentahistidine antibody. Closed
arrowhead indicates the intact rhHR23B-6His protein. Molecular
weight was indicated on the left side of the panel.

View larger version (39K):
[in a new window]
Fig. 4.
S5a binding activities of truncated
rhHR23B-6His proteins. A, summary of the mutant
6His-tagged rhHR23B (rhHR23B-6His) proteins. Ubiquitin,
ubiquitin-like region; SPTA-rich, four kinds of related
amino acids (S, P, T, and A) are predominant in this region;
UBA, ubiquitin-associated domain; XPC-binding,
XPC-binding domain; aa, amino acids. B, the
presence of precipitated rS5a was assessed by immunoblotting. 10%
input of rS5a is shown in lane 1. The proteins bound to the
nickel-chelating Sepharose beads are shown in lanes 2-13. Lane
2 is a negative control (no hHR23B protein) and lanes
3-13 correspond to lane numbers in panel A.

View larger version (45K):
[in a new window]
Fig. 5.
Effects of hHR23B-(1-87) and ubiquitin on
the interaction between rhHR23B and rS5a. A,
rhHR23B-6His (3 pmol) and GST-rS5a (15 pmol) were mixed, and the
materials bound to glutathione-Sepharose beads were recovered as
described under "Experimental Procedures." Bound proteins to
glutathione-Sepharose beads are shown in lanes 2-9. 50%
input of GST-rS5a and 20% input of rhHR23B-6His are shown in
lane 1. Either rhHR23B-(1-87) or ubiquitin was used as a
competitor with the indicated amount above each lane. B,
graphical representation of the results of panel A,
presented as the percentage of recovered rhHR23B-6His without
competitor. The signals of panel A were quantified using NIH
Image software. For proper comparison, the quantified amount of hHR23B
was normalized to the amount of the recovered S5a. The solid
bar represents the recovered hHR23B without any competitor. The
striped bars represent the amount of hHR23B in the presence
of hHR23B-(1-87). The gray bars represent the amount of
hHR23B in the presence of ubiquitin. The numbers at the
bottom correspond to the lane numbers in
panel A.

View larger version (61K):
[in a new window]
Fig. 6.
S5a binding activity of Ub-rhHR23B-6His.
rS5a was mixed with either Ub-rhHR23B-6His or rhHR23B-6His in buffer H
at 4 °C for 1 h, and the materials bound to the
nickel-chelating Sepharose beads were recovered. Bound proteins to the
nickel-chelating Sepharose beads without protein (lane 2),
with Ub-rhHR23B-6His (panel A, lane 3) or rNEDD8-6His
(panel B, lane 3), and with rhHR23B-6His (lane 4)
are shown. A and B, 20% input of rS5a is shown
in lane 1. The presence of precipitated rS5a was assessed by
immunoblotting using anti-S5a antibody.

View larger version (37K):
[in a new window]
Fig. 7.
Binding of rhHR23 proteins to truncated
6His-tagged rS5a. A, a summary of the mutant
6His-tagged rS5a proteins. The gray bar represents the
binding domain for the hHR23 proteins. GVDP repeat, region
which includes the GVDP tetrapeptide highly conserved among S5a
homologs; aa, amino acids. B and C,
the presence of precipitated rhHR23B (panel B) and rhHR23A
(panel C) was assessed by immunoblotting. 20% input of
rhHR23B (panel B) and rhHR23A (panel C) is shown
in each lane 1. The proteins bound to the nickel-chelating
Sepharose beads are shown in lanes 2-9. Lane 2 is a
negative control (no S5a protein), and lanes 3-9 correspond
to lane numbers in panel A.

View larger version (30K):
[in a new window]
Fig. 8.
Further analysis of the S5a region binding to
the hHR23 proteins. A, summary of the mutant
6His-tagged rS5a proteins. The amino acid sequence of S5a263-307 is
presented in the one-letter amino acid code. IAYAM, five
hydrophobic amino acids which are highly conserved in S5a homologs;
aa, amino acids. B and C, the presence
of precipitated rhHR23B (panel B) and rhHR23A (panel
C) was assessed by immunoblotting. 20% input of rhHR23B
(panel B) and rhHR23A (panel C) is shown in each
lane 1. The proteins bound to the nickel-chelating Sepharose
beads are shown in lanes 2-6. Lane 2 is a negative control
(no S5a protein) and lanes 3-6 correspond to lane
numbers in panel A.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Masutani, C.,
Sugasawa, K.,
Yanagisawa, J.,
Sonoyama, T.,
Ui, M.,
Enomoto, T.,
Takio, K.,
Tanaka, K.,
van der Spek, P. J.,
Bootsma, D.,
Hoeijmakers, J. H. J.,
and Hanaoka, F.
(1994)
EMBO J.
13,
1831-1843[Medline]
[Order article via Infotrieve]
2.
van der Spek, P. J.,
Visser, C. E.,
Hanaoka, F.,
Smit, B.,
Hagemeijer, A.,
Bootsma, D.,
and Hoeijmakers, J. H. J.
(1996)
Genomics
31,
20-27[CrossRef][Medline]
[Order article via Infotrieve]
3.
Sugasawa, K.,
Ng, J. M. Y.,
Masutani, C.,
Maekawa, T.,
Uchida, A.,
van der Spek, P. J.,
Eker, A. P. M.,
Rademakers, S.,
Visser, C.,
Aboussekhra, A.,
Wood, R. D.,
Hanaoka, F.,
Bootsma, D.,
and Hoeijmakers, J. H. J.
(1997)
Mol. Cell. Biol.
17,
6924-6931[Abstract]
4.
Watkins, J. F.,
Sung, P.,
Prakash, L.,
and Prakash, S.
(1993)
Mol. Cell. Biol.
13,
7757-7765 5.
Hofmann, K.,
and Bucher, P.
(1996)
Trends Biochem. Sci.
21,
172-173[CrossRef][Medline]
[Order article via Infotrieve]
6.
Masutani, C.,
Araki, M.,
Sugasawa, K.,
van der Spek, P. J.,
Yamada, A.,
Uchida, A.,
Maekawa, T.,
Bootsma, D.,
Hoeijmakers, J. H. J.,
and Hanaoka, F.
(1997)
Mol. Cell. Biol.
17,
6915-6923[Abstract]
7.
Sugasawa, K.,
Masutani, C.,
Uchida, A.,
Maekawa, T.,
van der Spek, P. J.,
Bootsma, D.,
Hoeijmakers, J. H. J.,
and Hanaoka, F.
(1996)
Mol. Cell. Biol.
16,
4852-4861[Abstract]
8.
van der Spek, P. J.,
Eker, A.,
Rademakers, S.,
Visser, C.,
Sugasawa, K.,
Masutani, C.,
Hanaoka, F.,
Bootsma, D.,
and Hoeijmakers, J. H. J.
(1996)
Nucleic Acids Res.
24,
2551-2559 9.
Bartel, P. L.,
Chien, C.-T.,
Sternglanz, R.,
and Fields, S.
(1993)
in
Cellular Interactions in Development: A Practical Approach
(Hartley, D. A., ed)
, pp. 153-179, Oxford University Press, Oxford
10.
Breeden, L.,
and Nasmyth, K.
(1985)
Cold Spring Harbor Symp. Quant. Biol.
50,
643-650 11.
Ohkuma, Y.,
Hashimoto, S.,
Wang, C. K.,
Horikoshi, M.,
and Roeder, R. G.
(1995)
Mol. Cell. Biol.
15,
4856-4866[Abstract]
12.
Hough, R.,
Pratt, G.,
and Rechsteiner, M.
(1987)
J. Biol. Chem.
262,
8303-8313 13.
Manley, J. L.,
Fire, A.,
Cano, A.,
Sharp, P. A.,
and Gefter, M. L.
(1980)
Proc. Natl. Acad. Sci. U. S. A.
77,
3855-3859 14.
Kumar, S.,
Yoshida, Y.,
and Noda, M.
(1993)
Biochem. Biophys. Res. Commun.
195,
393-399[CrossRef][Medline]
[Order article via Infotrieve]
15.
Tanaka, K.,
Waxman, L.,
and Goldberg, A. L.
(1983)
J. Cell Biol.
96,
1580-1585 16.
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
17.
Bradford, M. M.
(1976)
Anal. Biochem.
72,
248-254[CrossRef][Medline]
[Order article via Infotrieve]
18.
Li, L.,
Lu, X.,
Peterson, C.,
and Legerski, R.
(1997)
Mutat. Res.
383,
197-203[Medline]
[Order article via Infotrieve]
19.
Coux, O.,
Tanaka, K.,
and Goldberg, A. L.
(1996)
Annu. Rev. Biochem.
65,
801-847[CrossRef][Medline]
[Order article via Infotrieve]
20.
Kominami, K.,
DeMartino, G. N.,
Moomaw, C. R.,
Slaughter, C. A.,
Shimbara, N.,
Fujimuro, M.,
Yokosawa, H.,
Hisamatsu, H.,
Tanahashi, N.,
Shimizu, Y.,
Tanaka, K.,
and Toh-e, A.
(1995)
EMBO J.
14,
3105-3115[Medline]
[Order article via Infotrieve]
21.
Akiyama, K.,
Yokota, K.,
Kagawa, S.,
Shimbara, N.,
DeMartino, G. N.,
Slaughter, C. A.,
Noda, C.,
and Tanaka, K.
(1995)
FEBS Lett.
363,
151-156[CrossRef][Medline]
[Order article via Infotrieve]
22.
Deveraux, Q.,
van Nocker, S.,
Mahaffey, D.,
Vierstra, R.,
and Rechsteiner, M.
(1995)
J. Biol. Chem.
270,
29660-29663 23.
Ferrell, K.,
Deveraux, Q.,
van Nocker, S.,
and Rechsteiner, M.
(1996)
FEBS Lett.
381,
143-148[CrossRef][Medline]
[Order article via Infotrieve]
24.
Haynes, R. H.,
and Kunz, B. A.
(1981)
in
Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance
(Strathern, J. N.
, Jones, E. W.
, and Broach, J. R., eds)
, pp. 371-414, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
25.
Schauber, C.,
Chen,
Li,
Tongaonkar, P.,
Vega, I.,
Lambertson, D.,
Potts, W.,
and Madura, K.
(1998)
Nature
391,
715-718[CrossRef][Medline]
[Order article via Infotrieve]
26.
van Nocker, S.,
Deveraux, Q.,
Rechsteiner, M.,
and Vierstra, R. D.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
856-860 27.
Haracska, L.,
and Udvardy, A.
(1995)
Eur. J. Biochem.
231,
720-725[Medline]
[Order article via Infotrieve]
28.
Kominami, K.,
Okura, N.,
Kawamura, M.,
DeMartino, G. N.,
Slaughter, C. A.,
Shimbara, N.,
Chung, C. H.,
Fujimuro, M.,
Yokosawa, H.,
Shimizu, Y.,
Tanahashi, N.,
Tanaka, K.,
and Toh-e, A.
(1997)
Mol. Biol. Cell
8,
171-187[Abstract]
29.
Pusch, W.,
Jähner, D.,
and Ivell, R.
(1998)
Gene (Amst.)
207,
19-24[CrossRef][Medline]
[Order article via Infotrieve]
30.
van Nocker, S.,
Sadis, S.,
Rubin, D. M.,
Glickman, M.,
Fu, H.,
Coux, O.,
Wefes, I.,
Finley, D.,
and Vierstra, R. D.
(1996)
Mol. Cell. Biol.
16,
6020-6028[Abstract]
31.
Haracska, L.,
and Udvardy, A.
(1997)
FEBS Lett.
412,
331-336[CrossRef][Medline]
[Order article via Infotrieve]
32.
Fu, H.,
Sadis, S.,
Rubin, D. M.,
Glickman, M.,
van Nocker, S.,
Finley, D.,
and Vierstra, R. D.
(1998)
J. Biol. Chem.
273,
1970-1981 33.
Young, P.,
Deveraux, Q.,
Beal, R. E.,
Pickart, C. M.,
and Rechsteiner, M.
(1998)
J. Biol. Chem.
273,
5461-5467 34.
Friedberg, E. C.,
Walker, G. C.,
and Siede, W.
(1995)
DNA Repair and Mutagenesis
, pp. 607-618, American Society for Microbiology, Washington, D. C.
35.
Wilkinson, K. D.
(1995)
Annu. Rev. Nutr.
15,
161-189[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
Y. Li, L. Zheng, F. Corke, C. Smith, and M. W. Bevan Control of final seed and organ size by the DA1 gene family in Arabidopsis thaliana Genes & Dev., May 15, 2008; 22(10): 1331 - 1336. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sugasawa Xeroderma pigmentosum genes: functions inside and outside DNA repair Carcinogenesis, March 1, 2008; 29(3): 455 - 465. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Li, V. Su, W. E. Kurata, C. Jin, and A. F. Lau A Novel Connexin43-interacting Protein, CIP75, Which Belongs to the UbL-UBA Protein Family, Regulates the Turnover of Connexin43 J. Biol. Chem., February 29, 2008; 283(9): 5748 - 5759. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Mayor, J. Graumann, J. Bryan, M. J. MacCoss, and R. J. Deshaies Quantitative Profiling of Ubiquitylated Proteins Reveals Proteasome Substrates and the Substrate Repertoire Influenced by the Rpn10 Receptor Pathway Mol. Cell. Proteomics, November 1, 2007; 6(11): 1885 - 1895. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hamazaki, K. Sasaki, H. Kawahara, S.-i. Hisanaga, K. Tanaka, and S. Murata Rpn10-Mediated Degradation of Ubiquitinated Proteins Is Essential for Mouse Development Mol. Cell. Biol., October 1, 2007; 27(19): 6629 - 6638. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Fernandez, T. P. Miller, C. Denoyelle, J. A. Esteban, W.-H. Tang, A. L. Bengston, and M. S. Soengas Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: IMPACT ON TUMOR CELL DEATH J. Biol. Chem., January 13, 2006; 281(2): 1107 - 1118. [Abstract] [Full Text] [PDF] |
||||
![]() |